Vicore Pharma Holding AB (publ) VICO
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Maintain existing position; consider adding only on clear data points or a material price dip without fundamental deterioration.
The fully recruited ASPIRE study and cash runway into 2028 keep the risk profile unchanged while the binary topline readout in 2027 remains the main value driver.
Sentiment has improved slightly following the US listing and recruitment of a new CSO, but the market remains focused on the binary risk ahead of ASPIRE topline in 2027.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 22 Aug 2026 — Report confirms completed ASPIRE recruitment and extended cash runway, keeping binary risk profile unchanged ahead of 2027 readout.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Vicore Pharma is a Swedish biotech company developing AT2 receptor agonists (ATRAGs) for fibrotic and respiratory diseases. Its lead candidate buloxibutid (C21) is being evaluated in the global Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis (IPF). The company is pre-revenue and loss-making, but holds a strong cash position following a directed share issue.
Bull case
The US listing and completed ASPIRE recruitment strengthen the setup ahead of topline data in 2027.
Bear case
Valuation remains binary on ASPIRE results in mid-2027 with limited news flow until then.
Why this signal
The fully recruited ASPIRE study and cash runway into 2028 keep the risk profile unchanged while the binary topline readout in 2027 remains the main value driver.
Recent news
Vicore has presented at the Pareto Securities Healthcare Conference, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference and ERS Congress. Danske Bank raised its target price to 25 SEK. Citadel Advisors was noted as a new shorter. The share price has traded stably around 10–11 SEK.